What does the public data reveal about the Zoetis veterinary portfolio, and what should a veterinary clinic owner, practice manager, regulatory affairs specialist, or clinical director do with it?

As the largest standalone animal health company in the world, Zoetis occupies a critical position in veterinary medicine. Its portfolio serves as the primary therapeutic baseline for thousands of companion animal practices and livestock operations globally. For clinical decision-makers and practice operators, Zoetis' products are both the leading option in many key indications and a substantial operational cost center. Understanding the regulatory profile, active substances register, and real-world pharmacovigilance boundaries of this portfolio is essential for optimizing patient safety, mitigating clinical risks, and managing veterinary inventory.

This dossier analyzes the Zoetis veterinary portfolio using official regulatory records from the European Medicines Agency (EMA) centralized authorization registry, USDA APHIS Center for Veterinary Biologics, and the United States Food and Drug Administration (FDA) Center for Veterinary Medicine (CVM), together with aggregated post-market pharmacovigilance data from the FDA CVM public adverse-event database. It compares modern therapeutic classes — such as monoclonal antibodies (mAbs) — against traditional small-molecule interventions. Where VetMedGuide already publishes a product-specific deep dive, this dossier links to it rather than restating the detail.

---

Fast Answer

What is the therapeutic scope of the Zoetis veterinary portfolio, and what does clinical safety data reveal about its monoclonal antibodies?

The Zoetis veterinary portfolio spans six core therapeutic categories: vaccines, anti-infectives, parasiticides, medicated feed additives, diagnostics, and other companion animal pharmaceuticals. Standard clinical use of blockbuster brands like Apoquel (oclacitinib), Librela (bedinvetmab), and Simparica (sarolaner) is supported by extensive registration data.

However, public safety data highlights clear risk boundaries. An analysis of the FDA CVM public adverse-event database (a public extract dated June 2026 containing 1.34 million reports) identifies 141,919 unique reports naming Zoetis' five core companion-animal active substances shown below. Of these, roughly 44% carry a serious adverse-event flag. Feline osteoarthritis (OA) monoclonal antibody therapy frunevetmab (Solensia) accounts for 7,398 reports, while canine OA monoclonal antibody therapy bedinvetmab (Librela) accounts for 17,911 reports in the database.

These figures do not represent incidence rates or prove direct causation — the denominator of treated animals is not public, and report counts are dominated by who receives these drugs — but they define the statistical boundaries of passive safety reporting. For veterinary operators, the data underscores that while monoclonal antibodies offer highly targeted therapies that bypass hepatic and renal pathways, they require strict patient pre-screening, formal orthopedic staging, and structured client consent protocols prior to initiation.

---

What are the core therapeutic categories in the Zoetis veterinary portfolio?

The global commercial footprint of Zoetis is structured across six primary product categories. Each segment is characterized by distinct regulatory requirements, manufacturing complexities, and clinical workflows.

                  ┌──────────────────────────────────────────┐
                  │        Zoetis Veterinary Portfolio       │
                  └────────────────────┬─────────────────────┘
                                       │
         ┌───────────────┬─────────────┼───────────────┬───────────────┐
         ▼               ▼             ▼               ▼               ▼
    Parasiticides    Biologics   Dermatology     Diagnostics     Therapeutics
    (Simparica)      (Vaccines)   (Apoquel)     (Diagnostics)    (Monoclonals)

1. Parasiticides (Companion and Food Animal)

Parasite prevention represents one of the largest revenue drivers and client retention hooks in companion animal practice. The Zoetis parasiticide line is anchored by:

• Sarolaner: An isoxazoline-class insecticide and acaricide that acts as a GABA-gated chloride channel antagonist. It is marketed as a standalone chewable tablet (Simparica) and in combination with moxidectin and pyrantel (Simparica Trio) to provide broad-spectrum protection against heartworms, fleas, ticks, roundworms, and hookworms.
• Selamectin: A semi-synthetic avermectin marketed as a topical solution (Revolution and Revolution Plus, the latter containing sarolaner for enhanced feline tick coverage).
• Moxidectin: A second-generation macrocyclic lactone of the milbemycin class. It acts as an agonist at glutamate-gated chloride channels, causing flaccid paralysis in susceptible nematodes. It is utilized in injectable microsphere formats (ProHeart 6 and ProHeart 12) to provide multi-month heartworm prevention. Clinicians must account for potential toxicity in dogs homozygous for the ABCB1 (MDR1) gene mutation, as moxidectin is a substrate for P-glycoprotein, which limits drug entry across the blood-brain barrier.

2. Biologicals (Vaccines)

Zoetis maintains a broad catalog of immunizing products for companion animals, equine, swine, poultry, and cattle.

• Companion Animal (Vanguard): Includes core canine vaccines (DAPP—Distemper, Adenovirus, Parvovirus, Parainfluenza) and non-core vaccines (Leptospirosis, Lyme, Bordetella bronchiseptica). Feline lines cover FVRCP (Feline Viral Rhinotracheitis, Calicivirus, Panleukopenia) and FeLV (Feline Leukemia Virus).
• Livestock (Bovi-Shield, Suvaxyn, Zulvac): Focuses on prevention of reproductive and respiratory pathogens in cattle and swine, including Porcine Circovirus (PCV) and Bovine Respiratory Disease (BRD) complexes.

3. Dermatology (Immunomodulators)

Zoetis has dominated the canine atopic dermatitis market through two key molecules that target pruritic pathways:

• Oclacitinib Maleate (Apoquel): A synthetic Janus kinase (JAK) inhibitor that preferentially inhibits JAK1-dependent cytokines (such as IL-31, IL-2, IL-4, IL-6, and IL-13) involved in canine pruritus and inflammation.
• Lokivetmab (Cytopoint): A canine-derived monoclonal antibody that specifically binds and neutralizes IL-31, preventing it from binding to its co-receptor complex on peripheral nerves.

4. Monoclonal Antibodies (Pain Management)

The company has pioneered the commercialization of species-specific monoclonal antibodies targeting nerve growth factor (NGF) to manage chronic osteoarthritis pain:

• Bedinvetmab (Librela): A canine-derived IgG monoclonal antibody designed to neutralize NGF, reducing joint pain transmission and neurogenic inflammation.
• Frunevetmab (Solensia): A feline-derived IgG monoclonal antibody acting on the same NGF pathway, optimized for the feline immune system to prevent immunogenicity.
• Izenivetmab (Lenivia): Approved in Great Britain in May 2026, this represents the next generation of long-acting monoclonal antibodies for canine osteoarthritis pain, extending the dosing interval to once every three months.

5. Anti-Infectives

The anti-infective portfolio contains standard first-line and third-generation cephalosporins:

• Cefovecin Sodium (Convenia): An injectable third-generation cephalosporin that provides up to 14 days of therapeutic concentration from a single dose, widely used in cats and dogs for skin and soft tissue infections.
• Marbofloxacin (Zeniquin): A synthetic broad-spectrum fluoroquinolone.
• Ceftiofur (Excede, Naxcel): Livestock formulations providing long-acting therapeutic levels for respiratory infections.

6. Diagnostics and Practice Equipment

Following the acquisition of Abaxis, Zoetis integrates point-of-care diagnostic instruments under the Vetscan brand. These include:

• Vetscan VS2: A chemistry, electrolyte, and immunoassay analyzer utilizing dry reagent rotors.
• Vetscan HM5: A five-part differential hematology analyzer.
• Vetscan Imagyst: A multi-use platform leveraging artificial intelligence (AI) to perform fecal flotations, blood smears, and digital cytology transfers.

---

Monoclonal Antibodies vs. Traditional NSAIDs: A Comparative Analysis

To help clinical directors make informed therapeutic selections, it is necessary to contrast the pharmacokinetic and pharmacodynamic profiles of Zoetis’ novel monoclonal antibodies against traditional small-molecule nonsteroidal anti-inflammatory drugs (NSAIDs) like carprofen or meloxicam.

Feature	Monoclonal Antibodies (Librela, Solensia, Lenivia)	Traditional NSAIDs (Carprofen, Meloxicam, Robenacoxib)
Mechanism of Action	Neutralization of Nerve Growth Factor (NGF); blocks binding to TrkA and p75NTR receptors.	Inhibition of Cyclooxygenase (COX) enzymes (preferentially COX-2); blocks prostaglandin synthesis.
Target Pathway	Highly specific neurogenic pain pathway; does not address primary peripheral tissue inflammation.	Broad anti-inflammatory and analgesic pathway; reduces swelling, heat, and peripheral sensitization.
Metabolism & Clearance	Cellular catabolism via normal protein degradation into small peptides and amino acids.	Hepatic metabolism (cytochrome P450 pathway) followed by biliary and renal excretion.
Organ Burden	Bypasses hepatic and renal clearance; no metabolic load on liver or kidneys.	Places metabolic load on hepatic and renal systems; requires functional perfusion.
Administration Route	Subcutaneous injection performed exclusively by veterinary staff.	Oral (tablets, liquids) or subcutaneous injection; often administered at home by owners.
Dosing Frequency	Monthly (Librela, Solensia) or quarterly (Lenivia).	Daily (with minor exceptions like robenacoxib which is limited to consecutive 3-day use in cats).
Comorbidity Constraints	Contraindicated in breeding, pregnant, or lactating animals. Caution in patients with severe neurologic deficits.	Contraindicated in patients with active renal disease, hepatic insufficiency, or gastrointestinal ulcers.
Required Monitoring	Clinical joint assessment; monitoring for neurological changes or accelerated osteoarthritis.	Baseline and periodic serum biochemistry (ALT, AST, ALP, BUN, Creatinine) every 6–12 months.

---

Analyzing openFDA Adverse Event Reports for Zoetis Active Substances

An evaluation of the public safety database maintained by the FDA CVM (a public extract dated June 2026, containing 1.34 million reports) reveals distinct reporting profiles for Zoetis' signature companion animal products. When reviewing these metrics, clinicians must remember that adverse event reports represent passive surveillance data. They show the raw number of complaints submitted by veterinarians and pet owners; they do not establish baseline incidence rates (since the total number of treated animals is not public) and do not confirm that the drug caused the clinical sign.

Aggregated across the five core active substances below, the database holds 141,919 unique reports, of which about 44% carry a serious adverse-event flag. Report counts are matched on active_ingredient (brand names are masked in the public file) and de-duplicated by unique report ID.

Zoetis Ingredient Performance Matrix

Active Ingredient (Brand Name)	Total Reports	Serious Adverse Events	Serious AE %	Top Reported Clinical Signs
Oclacitinib (Apoquel)	29,296	8,592	29.3%	Lack of efficacy, vomiting, diarrhea, lethargy, elevated ALT, neoplasia.
Bedinvetmab (Librela)	17,911	11,039	61.6%	Death by euthanasia, lethargy, polydipsia, ataxia, vomiting, polyuria, seizures.
Frunevetmab (Solensia)	7,398	4,263	57.6%	Skin scab, vomiting, lethargy, lack of efficacy, pruritus, weight loss.
Sarolaner (Simparica)	76,979	35,564	46.2%	Vomiting, seizures, lack of efficacy (heartworm/tick), diarrhea, lethargy.
Cefovecin (Convenia)	13,080	4,915	37.6%	Lethargy, anorexia, vomiting, death, diarrhea, lack of efficacy.

Note that these serious-flag rates are not comparable across rows as measures of drug risk: the monoclonal antibodies (Librela, Solensia) are injected almost exclusively into geriatric patients, while oclacitinib's reports lean heavily on efficacy complaints. Across the five ingredients, roughly 6.7% of reports list a fatal outcome (Died or Euthanized). For product-specific safety detail, VetMedGuide publishes deeper analyses of Librela, Solensia, Apoquel, Simparica Trio, and Convenia; this dossier focuses on the portfolio-level picture.

Clinical Interpretation of Monoclonal Antibody Safety Data

The high serious-flag rates for bedinvetmab (61.6%) and frunevetmab (57.6%) are substantial, but they must be interpreted within their clinical context:

1. Patient Demographics: Monoclonal antibodies for osteoarthritis are administered almost exclusively to geriatric feline and canine populations. This cohort possesses significant baseline comorbidities, including chronic kidney disease (CKD), cognitive dysfunction, subclinical spinal disease, and neoplasia. Natural disease progression in these patients is frequently captured in post-market reports.
2. Neurological vs. Orthopedic Overlap: In dogs receiving Librela, signs such as ataxia, hind limb weakness, and urinary incontinence are frequently reported. NGF plays a critical role in maintaining sensory neuron health. Clinicians must distinguish between a patient experiencing a progression of pre-existing degenerative myelopathy or lumbosacral stenosis and a direct drug reaction. In December 2024 the FDA issued a Dear Veterinarian letter about Librela, and the U.S. label was updated in 2025 to add a post-approval adverse-event section.
3. Dermatological Signs in Cats: Solensia reports show a high concentration of facial pruritus, excoriation, and alopecia. This is a recognized adverse effect, likely due to localized immunogenicity or altered cutaneous sensation mediated by NGF inhibition. It typically resolves upon discontinuation of the therapy.

---

What does the EMA data reveal about Zoetis' European biologics pipeline?

The European Medicines Agency (EMA) Union Register provides an analytical window into Zoetis' European manufacturing operations and pipeline strategy. Centralized approvals are valid across all EU Member States, representing a highly standardized regulatory threshold compared to national-level registrations. Representative centrally authorized products listed under Zoetis' European entities (principally Zoetis Belgium SA) include:

1. Versiguard SARS-CoV-2: A recombinant vaccine authorized for certain animals (including zoo species) to mitigate SARS-CoV-2 transmission — one of the first such veterinary authorizations in the EU.
2. Zulvac 8 Bovis: An inactivated vaccine targeting Bovine Bluetongue Virus Serotype 8, crucial for livestock transport and disease containment inside the EU.
3. Suvaxyn PCV: A subunit vaccine targeting Porcine Circovirus Type 2, a major pathogen causing post-weaning multisystemic wasting syndrome (PMWS) in swine.
4. Zulvac 1 Ovis: Inactivated vaccine for Bluetongue Virus Serotype 1 in sheep.
5. Zulvac 1 Bovis: Inactivated vaccine for Bluetongue Virus Serotype 1 in cattle.
6. RevitaCAM: A meloxicam oromucosal spray (a generic-reference formulation) authorized for the alleviation of pain and inflammation in acute and chronic musculoskeletal disorders in dogs.

A note on reading the register: it also retains Slentrol (dirlotapide), Zoetis's first-in-class canine anti-obesity drug (an MTP inhibitor that limits intestinal fat absorption), but Slentrol's EU marketing authorization was voluntarily withdrawn at the company's request and is no longer authorized — a reminder that "present in the register" is not the same as "currently on the market." The exact count of active authorizations shifts as products are added or withdrawn, so treat the list above as illustrative rather than exhaustive.

Key Takeaway for Regulatory Teams

While the US market utilizes national USDA APHIS licensing for veterinary biologics (which bypasses the FDA CVM entirely), the European Union manages all veterinary biologics via a unified procedure under the EMA. The presence of multiple Zulvac and Suvaxyn formulations in the centralized registry highlights Zoetis' focus on protecting large-scale European swine and cattle operations from high-impact transboundary infectious diseases.

---

USDA/CVB Biologics Licensing vs. FDA/CVM Drug Approvals

A common source of confusion in the veterinary industry is the split regulatory framework for animal products in the United States. Practice managers and clinical leads must navigate distinct pathways depending on whether a product is classified as a drug, a biologic, or a pesticide:

1. The FDA Center for Veterinary Medicine (CVM)

The FDA CVM has regulatory authority over animal drugs under the Federal Food, Drug, and Cosmetic Act (FD&CA). A product is classified as a drug if it is intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease in animals, and is not a biologic or pesticide.

• Examples: Apoquel (oclacitinib), Librela (bedinvetmab), Solensia (frunevetmab), Convenia (cefovecin).
• Process: Requires a New Animal Drug Application (NADA) approval, which mandates extensive target animal safety (TAS) studies, target animal efficacy (TAE) studies, and Chemistry, Manufacturing, and Controls (CMC) validation.

2. The USDA APHIS Center for Veterinary Biologics (CVB)

The USDA CVB regulates veterinary biologics—including vaccines, bacterins, diagnostics, and select immunomodulators—under the Virus-Serum-Toxin Act (VSTA). Biologics act through an immune-mediated mechanism of action.

• Examples: Vanguard vaccines, Defensor Rabies vaccine, Cytopoint (lokivetmab).
• Process: Instead of an NADA, biologics receive a USDA Veterinary Biological Product License. The safety and efficacy standards focus on purity, safety, potency, and efficacy (PSPE), often utilizing challenge studies rather than the multi-phase clinical field trials required by the FDA CVM.

3. The Environmental Protection Agency (EPA)

The EPA regulates topical parasiticides that function as pesticides under the Federal Insecticide, Fungicide, and Rodenticide Act (FIFRA).

• Examples: Topical spot-on products containing permethrin or fipronil. (Note: oral parasiticides like Simparica contain active ingredients absorbed systemically and are therefore regulated as drugs by the FDA CVM).

This regulatory split creates operational differences for clinics. For example, adverse event reporting for Cytopoint (USDA-regulated) goes to the USDA portal, whereas reporting for Librela (FDA-regulated) goes to the FDA CVM portal, segmenting the pharmacovigilance data streams.

---

Clinical Staging and Patient Staging Protocols

To manage the risk boundaries highlighted by the openFDA and EMA registries, companion animal practices should adopt a formal staging protocol for patients considered for monoclonal antibody therapy.

       ┌────────────────────────────────────────────────────────┐
       │             Monoclonal Antibody Candidate              │
       └───────────────────────────┬────────────────────────────┘
                                   │
                    Perform Orthopedic & Neuro Exam
                                   │
                 ┌─────────────────┴─────────────────┐
                 ▼                                   ▼
        Neurological Deficits?              Clean Orthopedic Exam?
        (Ataxia, DM, LS Stenosis)           (Isolated OA Pain)
                 │                                   │
                 ▼                                   ▼
         [High Risk Patient]                [Standard Candidate]
      Consider NSAID or Gabapentin;        Initiate Librela/Solensia;
      Monitor closely if mAb chosen.      Schedule 14-Day Call Follow-Up.

1. The Pre-Screening Exam

Prior to administering the first dose of Librela or Solensia, the clinician must perform a comprehensive orthopedic and neurological examination.

• Neurological Baseline: Check conscious proprioception (CP), spinal reflexes, and evaluate for lumbosacral pain. In dogs with signs of degenerative myelopathy (DM) or lumbosacral stenosis, NGF inhibition could theoretically accelerate proprioceptive decline by reducing sensory neuron support.
• Orthopedic Staging: Differentiate osteoarthritis pain from neurological weakness. A dog that is weak in the hindquarters due to spinal cord compression will not benefit from Librela and may appear to decline rapidly.

2. The Patient Consent Form

Practices should implement a client educational disclosure that notes:

• The mechanism of action (targeting NGF, not an anti-inflammatory).
• The requirement for monthly administration to maintain efficacy (except for Lenivia, which utilizes a 3-month schedule).
• The potential for mild, transient side effects (such as localized skin reactions or mild lethargy).
• A clear instruction to report any new neurological signs (such as dragging paws, difficulty rising, or urinary accidents) immediately.

3. Monitoring and Discontinuation Rules

• Feline Patients: If a cat develops severe facial pruritus or self-trauma after a Solensia injection, the therapy should be suspended. Symptomatic management with corticosteroids or gabapentin may be required until the frunevetmab clears the system (which can take 6–8 weeks due to the half-life of IgG antibodies).
• Canine Patients: Efficacy should be evaluated after the second consecutive dose. If the patient shows no measurable improvement in mobility or pain scores (assessed via the Canine Brief Pain Inventory) by day 60, the therapy should be discontinued, and the clinician should pivot to alternative pain management pathways.

4. Clinical Trial Outcomes vs. Post-Market Realities

During pivotal clinical trials, bedinvetmab and frunevetmab demonstrated excellent safety profiles with low reporting rates of serious adverse events. However, post-market surveillance introduces variables that clinical trials control:

• Comorbidity Mix: Trial protocols exclude animals with advanced renal disease, neurological diseases, or unstable metabolic conditions. In real-world clinics, senior pets frequently suffer from multiple conditions, which can lead to unexpected drug interactions or accelerated clinical decline.
• Owner Expectations: While trials rely on structured scoring, owners in clinic settings may mistake cognitive decline or spinal arthritis progression for drug failure or toxicity, highlighting the necessity of clinical staging.

---

Matching the pain drug to the patient: mAb vs NSAID in practice

The monoclonal-antibody versus NSAID table above describes mechanism; in a clinic, the decision is driven by the patient in front of you. A workable selection logic:

• Geriatric cat with CKD and OA pain. Solensia (frunevetmab) is usually preferred because it bypasses hepatic and renal clearance and avoids the feline NSAID renal-safety ceiling that limits drugs like meloxicam and robenacoxib to short, carefully screened courses. Confirm stable renal status and counsel the owner that facial pruritus/alopecia after injection is the reaction to watch for.
• Geriatric dog with OA pain and no contraindications. Librela (bedinvetmab) is a strong option, especially for owners who struggle with daily oral dosing. The pre-screening exam must rule out neurologic weakness (degenerative myelopathy, lumbosacral stenosis) because a dog declining from spinal disease will not improve on an NGF inhibitor and may appear to "get worse." NSAIDs remain appropriate when renal and hepatic panels are clean and the dog tolerates daily medication.
• Dog with active renal disease, hepatic insufficiency, or GI ulceration. Avoid traditional NSAIDs; a monoclonal antibody that bypasses those organs is the safer analgesic route. Conversely, for acute surgical or inflammatory pain, a short-acting NSAID (robenacoxib) or a multimodal perioperative plan usually outperforms an NGF inhibitor, which is built for chronic, not acute, pain.
• Breeding, pregnant, or lactating animal. Both Librela and Solensia are contraindicated; fall back to NSAIDs or non-drug modalities as appropriate to the species and stage.

The recurring principle across Zoetis's pain portfolio is that the monoclonal antibodies win on organ-sparing safety in fragile geriatric patients, while NSAIDs win on anti-inflammatory breadth and acute pain — they are complements, not substitutes, and the staging exam is what decides which a patient gets.

Vetscan diagnostics in the practice workflow

Zoetis's diagnostics business (built on the Abaxis acquisition) turns the Vetscan line into a practice-operations decision as much as a clinical one. The Vetscan VS2 chemistry analyzer runs comprehensive panels, electrolytes, and specialty tests (T4, bile acids) from a small whole-blood sample on single-use rotors — suited to in-clinic same-visit results for pre-anesthetic screening and senior wellness. The Vetscan HM5 provides a five-part differential CBC, and the Vetscan Imagyst uses cloud-based AI plus board-certified pathologist review for fecal, blood-smear, and cytology reads.

For a practice manager, the relevant questions are throughput, cost-per-test, rotor/supply inventory, and integration with the practice information management system — not just analytic capability. Same-visit chemistry changes the client conversation (decisions during the visit rather than a callback), but the per-rotor cost and the need to keep rotors in date have to be modeled against a reference-lab send-out. The diagnostics line also reinforces the rest of Zoetis's portfolio: a cat flagged with elevated renal values on a VS2 during a Solensia workup is exactly the patient where the mAb-versus-NSAID decision above tips toward the organ-sparing monoclonal antibody. That linkage — diagnostics informing the drug choice — is one reason a Zoetis-heavy practice tends to standardize across the Vetscan and pharmaceutical lines together.

FAQ: Common Clinical Questions

What is the difference between Librela and Apoquel in clinical safety profiles?

Librela (bedinvetmab) and Apoquel (oclacitinib) represent entirely different therapeutic classes and target distinct physiological pathways:

• Mechanism: Librela is a monoclonal antibody that targets nerve growth factor (NGF) to control osteoarthritis pain. Apoquel is a small-molecule synthetic Janus kinase (JAK) inhibitor that targets JAK1-dependent cytokines (such as IL-31) to control allergic pruritus and atopic dermatitis.
• Metabolism: Librela bypasses the liver and kidneys, undergoing normal protein catabolism. Apoquel is metabolized hepatically and excreted via the renal system, requiring regular blood monitoring (CBC and chemistry) during long-term therapy.
• Immune System Impact: Librela does not suppress the immune system. Apoquel, as a JAK inhibitor, can modulate immune responses; its label warns of potential susceptibility to infections, demodicoses, and the risk of exacerbating pre-existing neoplasia.
• Adverse Events: Librela adverse events are predominantly neurological or orthopedic (ataxia, hind limb weakness, urinary incontinence). Apoquel reports are dominated by gastrointestinal signs (vomiting, diarrhea) and skin changes (masses, histiocytomas, localized infections).

Does Zoetis manufacture point-of-care diagnostic instruments for vet clinics?

Yes. Through its Vetscan brand (developed by Abaxis), Zoetis designs, manufactures, and supports a full suite of in-house laboratory analyzers. These instruments connect directly to modern practice information management systems (PIMS) and utilize specialized testing profiles:

• Vetscan VS2 Chemistry Analyzer: Utilizes single-use plastic rotors containing freeze-dried reagents to perform comprehensive chemistry, electrolyte, and specialty panels (such as canine T4 and bile acids) from 100 microliters of whole blood, plasma, or serum.
• Vetscan HM5 Hematology Analyzer: A impedance-based five-part differential analyzer that provides complete blood counts (CBC) with cell histograms.
• Vetscan Imagyst: A digital microscopy platform that utilizes cloud-based artificial intelligence to classify fecal parasites, analyze canine/feline blood smears, and perform rapid digital cytology readings reviewed by board-certified clinical pathologists.

When should a dog switch from an NSAID to Librela (or add Librela)?

The clearest trigger is organ-status, not efficacy alone. If baseline or monitoring bloodwork shows declining renal or hepatic function on an NSAID, continuing a COX-inhibitor becomes risky, and Librela — which is cleared by protein catabolism rather than hepatic/renal routes — is a logical analgesic alternative for chronic OA pain. Librela is also a reasonable choice for the geriatric dog on multiple concurrent medications where adding another hepatically-metabolized drug is undesirable. The reverse switch (Librela to an NSAID) is less common but applies when the pain has a strong inflammatory component the mAb does not address, or when a neurologic adverse-event signal appears. Either transition should be guided by a staging exam, not by chasing a particular serious-flag percentage from the dataset.

How should a clinic interpret the high serious-flag rate for Librela and Solensia?

The 61.6% serious-flag rate for bedinvetmab and 57.6% for frunevetmab look alarming in isolation, but they reflect who receives these drugs — almost exclusively elderly dogs and cats with advanced osteoarthritis and frequent comorbidities — far more than they reflect drug-attributable harm. The UK Veterinary Medicines Directorate's own Librela assessment concluded that death following administration is rare (on the order of 1–10 per 10,000 treated animals) and that it is unclear whether the small subset of dogs that deteriorate within roughly 14 days of an injection are experiencing a product-related effect. The honest read: these monoclonal antibodies remain appropriate for carefully selected patients, the geriatric baseline risk is real and must be communicated, and any new neurologic sign after a dose should pause therapy pending veterinary reassessment. VetMedGuide's Librela side-effects analysis covers the death-outcome signal in detail.

What is the difference between Cytopoint and Apoquel, and why does the regulator differ?

Both treat allergic itch, but through different mechanisms and under different U.S. regulators. Cytopoint (lokivetmab) is a monoclonal antibody that neutralizes IL-31 and is licensed by the USDA as a veterinary biologic. Apoquel (oclacitinib) is a small-molecule JAK1 inhibitor approved by the FDA CVM as a drug. That regulatory split is not a trivia point: it determines where adverse events are reported (USDA portal for Cytopoint, FDA CVM for Apoquel), which is why Apoquel appears in the FDA pharmacovigilance data above while Cytopoint does not — the two products flow into different reporting systems. Clinically, Cytopoint suits dogs that need an injectable, non-immunosuppressing option; Apoquel suits oral daily control but carries the JAK-inhibitor infection and neoplasia cautions.

How does Lenivia (izenivetmab) change the canine OA monoclonal-antibody landscape?

Lenivia is the newest entrant in Zoetis's anti-NGF line, approved by the UK VMD in May 2026 (with an EU marketing authorization also granted in 2025). Its differentiator is duration: dosed roughly once every three months rather than monthly, it halves or quarters the number of clinic visits a chronic-OA dog needs for pain control. For practices, that changes both the revenue model (fewer injection events per patient per year) and the compliance story (a long-acting option suits owners who struggle with monthly visits). The same patient-selection logic still applies — anti-NGF therapy is for chronic OA pain in appropriately staged patients, not a substitute for an anti-inflammatory in acute settings — and the neurologic monitoring cautions carry over from the Librela experience. As Lenivia reaches more markets, the practical question will be whether a quarterly schedule improves persistence enough to offset the visit-frequency tradeoff, particularly in the geriatric cohort where clinic visits themselves can be stressful.

How does Zoetis's portfolio compare to Elanco's and Boehringer's?

Each of the big three has a recognizable center of gravity. Zoetis is the broadest — strong across vaccines, parasiticides, dermatology, anti-infectives, diagnostics, and the monoclonal-antibody pain franchise — and it leads in novel biologics (Librela, Solensia, Lenivia, Cytopoint). Elanco is parasiticide- and dermatology-led, sharpened by the Bayer acquisition and by the Zenrelia/Befrena dermatology push. Boehringer is companion-animal chronic-care and livestock-vaccine led, anchored by NexGard, Vetmedin, and Senvelgo alongside its large swine and cattle biologics business. For a practice, the practical implication is that a Zoetis-heavy formulary tends to show up most in dermatology, pain, and in-house diagnostics, while the cross-company comparisons that matter most (Apoquel vs Zenrelia, Librela vs NSAIDs, NexGard vs Simparica vs Credelio) cut across these portfolios rather than sitting inside any one of them — which is exactly why VetMedGuide's per-product deep dives link out from this dossier. Reading the three companies side by side also makes one pattern clear: the highest-value clinical decisions are almost always product-versus-product, not company-versus-company, and a well-staged patient is what makes the choice defensible. Keeping that framing in mind is what turns a portfolio dossier from a manufacturer overview into a usable clinical and operational reference.

---

Sources

• European Medicines Agency Union Register of Veterinary Medicinal Products: Centralized Authorizations for Zoetis Belgium SA. https://ec.europa.eu/health/documents/community-register/html/index_en.htm
• FDA Center for Veterinary Medicine (CVM) Approved Animal Drug Database: New Animal Drug Applications (NADA) for oclacitinib, bedinvetmab, frunevetmab, and sarolaner. https://www.fda.gov/about-fda/center-veterinary-medicine
• FDA CVM Drug Adverse Event Registry: Aggregated Pharmacovigilance Reports for oclacitinib, bedinvetmab, frunevetmab, sarolaner, and cefovecin (records processed through June 2026). https://www.fda.gov/animal-veterinary/safety-reports/adverse-drug-experience-reports
• USDA Animal and Plant Health Inspection Service (APHIS) Center for Veterinary Biologics Product Summaries. https://www.aphis.usda.gov/veterinary-biologics/product-summaries
• Great Britain Veterinary Medicines Directorate (VMD) Product Register: Lenivia (izenivetmab) authorization records (May 2026). https://www.gov.uk/government/organisations/veterinary-medicines-directorate